Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Inclusion Criteria: * measurable metastatic adenocarcinoma of the colon or rectum * no prior systemic therapy for metastatic disease * adjuvant therapy must have been completed \>/=12 months prior to recurrence, prior radiotherapy permitted but must have been completed \> 6 months prior to study entry * must have tumor tissue available for EGFR and thymidine phosphorylase evaluation * ECOG PS 0-1 * age \>/= 18 * adequate organ function: WBC\>/=3,000, ANC \>/=1,500, platelets\>/= 100,000, total bilirubin \</= 1.5X ULN, AST\&ALT \</= 2.5X ULN, create clearance \>/= 50mL/min * negative pregnancy test w/in 72 hours of treatment for women of child bearing potential * ability to understand and willing to sign written ICF * able to swallow and absorb oral medication Exclusion Criteria: * medical or psychiatric condition which would potentially pose risk to patient by participation (i.e. but not limited to:uncontrolled hypertension, MI w/in 6 months,CNS disease, pregnancy or nursing) * history of neoplasm (other than non-metastatic skin cancer or carcinoma in situ of cervix) w/in 5 years * surgical procedure (not including closed biopsy or access port placement), open biopsy, significant traumatic injury w/in 28 days of registration or anticipation of need for surgical procedure while on study, fine needle aspiration or core biopsy w/in 7 days of registration * urine protein:creatinine ration \>/=1.0 at screening * evidence of bleeding diathesis or coagulopathy (in absence of anticoagulation) * prior severe infusion reaction to MAB or allergic reaction to capecitabine or oxaliplatin * underlying neuropathy \>/= grade 2 * TIA or CVA w/in 6 months